BIIB Financials: Biogen Inc AI Analysis



Financials

BIIB Financial

Biogen Inc

$217.5

2.32%

$4.94

At close: Aug 18, 16:00:00 GMT-4

$217.5

Pre-market: Aug 19, 09:45:59 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$212.55

Open

$215.35

Day's Range

$215.07 - $217.99

52 week range

$131.52 - $219.72

Volume

43.8K

Avg.Volume

1.2M

Dividend yield

EPS (TTM)

5.65

Market Cap

$32.1B

What is BIIB?

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Features

Markets

News

Breakdown	TTM	06/30/2026	03/31/2026	12/31/2025	09/30/2025	06/30/2025
Revenue	10,027	2,736	2,477	2,279	2,534	2,645
Revenue Growth (YoY)	0%	3%	2%	-7%	3%	7%
Cost of Revenue	2,607	776	661	495	674	605
Gross Profit	7,420	1,959	1,816	1,783	1,860	2,040
Selling, General & Admin	2,589	709	607	679	592	581
Research & Development	2,002	529	539	502	431	393
Operating Expenses	5,198	1,410	1,303	1,318	1,165	1,115
Other Non Operating Income (Expenses)	30	3	-1	12	15	-3
Pretax Income	1,011	132	377	-56	557	744
Income Tax Expense	176	34	58	-7	90	109
Net Income	834	97	319	-48	466	634
Net Income Growth	-46%	-85%	33%	-118%	20%	9%
Shares Outstanding (Diluted)	148.7	148.7	148.4	146.8	147.1	146.7
Shares Change (YoY)	1%	1%	1%	1%	1%	1%
EPS (Diluted)	5.61	0.65	2.15	-0.33	3.17	4.32
EPS Growth	-46%	-85%	31%	-118%	19%	8%
Free Cash Flow	2,540	308	559	451	1,221	134
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	74%	71.6%	73.31%	78.23%	73.4%	77.12%
Operating Margin	22.16%	20.06%	20.71%	20.4%	27.38%	34.93%
Profit Margin	8.31%	3.54%	12.87%	-2.1%	18.38%	23.96%
Free Cash Flow Margin	25.33%	11.25%	22.56%	19.78%	48.18%	5.06%
EBITDA	2,794	717	649	597	829	1,051
EBITDA Margin	27.86%	26.2%	26.2%	26.19%	32.71%	39.73%
D&A For EBITDA	572	168	136	132	135	127
EBIT	2,222	549	513	465	694	924
EBIT Margin	22.16%	20.06%	20.71%	20.4%	27.38%	34.93%
Effective Tax Rate	17.4%	25.75%	15.38%	12.5%	16.15%	14.65%

Breakdown

TTM

06/30/2026

03/31/2026

12/31/2025

09/30/2025

06/30/2025

Revenue

10,027

2,736

2,477

2,279

2,534

2,645

Revenue Growth (YoY)

-7%

Cost of Revenue

2,607

776

661

495

674

605

Gross Profit

7,420

1,959

1,816

1,783

1,860

2,040

Selling, General & Admin

2,589

709

607

679

592

581

Research & Development

2,002

529

539

502

431

393

Operating Expenses

5,198

1,410

1,303

1,318

1,165

1,115

Other Non Operating Income (Expenses)

-1

-3

Pretax Income

1,011

132

377

-56

557

744

Income Tax Expense

176

-7

109

Net Income

834

319

-48

466

634

Net Income Growth

-46%

-85%

33%

-118%

20%

Shares Outstanding (Diluted)

148.7

148.4

146.8

147.1

146.7

Shares Change (YoY)

EPS (Diluted)

5.61

0.65

2.15

-0.33

3.17

4.32

EPS Growth

-46%

-85%

31%

-118%

19%

Free Cash Flow

2,540

308

559

451

1,221

134

Free Cash Flow Per Share

Gross Margin

74%

71.6%

73.31%

78.23%

73.4%

77.12%

Operating Margin

22.16%

20.06%

20.71%

20.4%

27.38%

34.93%

Profit Margin

8.31%

3.54%

12.87%

-2.1%

18.38%

23.96%

Free Cash Flow Margin

25.33%

11.25%

22.56%

19.78%

48.18%

5.06%

EBITDA

2,794

717

649

597

829

1,051

EBITDA Margin

27.86%

26.2%

26.19%

32.71%

39.73%

D&A For EBITDA

572

168

136

132

135

127

EBIT

2,222

549

513

465

694

924

EBIT Margin

22.16%

20.06%

20.71%

20.4%

27.38%

34.93%

Effective Tax Rate

17.4%

25.75%

15.38%

12.5%

16.15%

14.65%

Follow-Up Questions

What are Biogen Inc's key financial statements?



According to the latest financial statement (Form-10K), Biogen Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for BIIB?



Biogen Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Biogen Inc's revenue broken down by segment or geography?



Biogen Inc largest revenue segment is Other, at a revenue of 2,771,200,000 in the most earnings release.For geography, United States is the primary market for Biogen Inc, at a revenue of 3,547,900,000.

Is Biogen Inc profitable?



no, according to the latest financial statements, Biogen Inc has a net loss of $0

Does Biogen Inc have any liabilities?



no, Biogen Inc has liability of 0

How many outstanding shares for Biogen Inc?



Biogen Inc has a total outstanding shares of 0

Biogen Inc (BIIB) Financial

BIIB Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is BIIB?

Biogen Inc (BIIB) Financial

BIIB Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is BIIB?

BIIB Income

Follow-Up Questions

What are Biogen Inc's key financial statements?

What are the key financial ratios for BIIB?

How is Biogen Inc's revenue broken down by segment or geography?

Is Biogen Inc profitable?

Does Biogen Inc have any liabilities?

How many outstanding shares for Biogen Inc?